(Q37947108)

25 August 2017

The role of antimalarial agents in the treatment of SLE and lupus nephritis (English)

1 reference

25 August 2017

0 references

Senq-J Lee

1

1 reference

25 August 2017

Earl Silverman

series ordinal

2

1 reference

25 August 2017

Joanne M Bargman

series ordinal

3

1 reference

25 August 2017

language of work or name

English

0 references

publication date

18 October 2011

1 reference

Nature Reviews Nephrology

25 August 2017

1 reference

25 August 2017

7

1 reference

25 August 2017

12

1 reference

25 August 2017

718-729

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneph.2011.150

25 August 2017

0 references

cites work

Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Bioavailability of hydroxychloroquine tablets in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Occasional series: lupus around the world systemic lupus erythematosus research in the Asia-Pacific region: a co-ordinated and co-operative approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

New concepts in antimalarial use and mode of action in dermatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Hydroxychloroquine treatment of hypercalcemia in a patient with sarcoidosis undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

The antiphospholipid syndrome and SLE: is there a clue in the link between complement and coagulation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

The biology behind the new therapies for SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Inhibition of mitogen-activated protein kinase signaling by chloroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Hydroxychloroquine potentiates Fas-mediated apoptosis of rheumatoid synoviocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Studies on the mechanism of inhibition of chemotactic tripeptide stimulated human neutrophil polymorphonuclear leucocyte superoxide production by chloroquine and hydroxychloroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

4-Aminoquinoline antimalarials enhance UV-B induced c-jun transcriptional activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Effect of chloroquine phosphate treatment on serum MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Toll-like receptor 9 dependent activation of MAPK and NF-kB is required for the CpG ODN-induced matrix metalloproteinase-9 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Antimalarials in the management of discoid and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Controlled trial with chloroquine diphosphate in systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Anti-malarials and Lupus in West Africa use and lupus in Africans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Prevalence and factors associated with dyslipoproteinemias in Brazilian systemic lupus erythematosus patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Chloroquine augments the binding of insulin to its receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Biochemical characterization of ADP-ribose polymer metabolism in SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas--a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Metabolic syndrome in Argentinean patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

p53 is required for chloroquine-induced atheroprotection but not insulin sensitization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Evaluation of risk factors that contribute to high prevalence of premature atherosclerosis in Chinese premenopausal systemic lupus erythematosus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Atherosclerotic plaque in carotid arteries in systemic lupus erythematosus: frequency and associated risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Vascular stiffness in women with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Vascular elasticity of systemic lupus erythematosus patients is associated with steroids and hydroxychloroquine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Antimalarials may influence the risk of malignancy in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Protective effect of hydroxychloroquine on renal damage may be biased: comment on the article by Pons-Estel et al.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Have some beneficial effects of hydroxychloroquine been overestimated? Potential biases in observational studies of drug effects: comment on the article by Pons-Estel et al.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Antimalarial drugs and pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Lupus nephritis and renal disease in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Hydroxychloroquine in lupus pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Different effects of chloroquine and hydroxychloroquine on lysosomal function in cultured retinal pigment epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Using multifocal ERG ring ratios to detect and follow Plaquenil retinal toxicity: a review : Review of mfERG ring ratios in Plaquenil toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Hydroxychloroquine-induced hyperpigmentation: the staining pattern

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

The role of antimalarials in the exacerbation of psoriasis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Iatrogenic phospholipidosis mimicking Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Predictors of major infections in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Lupus nephritis and Raynaud's phenomenon are significant risk factors for vascular thrombosis in SLE patients with positive antiphospholipid antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Sustained remission of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: A study of one hundred thirty‐three cases compared with a control group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Pregnancy and systemic lupus erythematosus: review of clinical features and outcome of 51 pregnancies at a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Long-term effectiveness of antimalarial drugs in rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Hydroxychloroquine, dosage parameters and retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Cardiomyopathy related to antimalarial therapy with illustrative case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

The cardiac safety of chloroquine phosphate treatment in patients with systemic lupus erythematosus: the influence on arrhythmia, heart rate variability and repolarization parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Cardiac toxicity secondary to long term treatment with chloroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Chloroquine -induced hair depigmentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Chloroquine psychosis masquerading as PCP: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Quinacrine (atabrine) in treatment of systemic and discoid lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Systemic lupus erythematosus in the elderly: antimalarials in disease remission

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells.

31 March 2020

1 reference

12 December 2020

The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE.

1 reference

12 December 2020

Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases.

1 reference

12 December 2020

Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development.

1 reference

12 December 2020

The history of antimalarials.

1 reference

12 December 2020

Discontinuation of antimalarial drugs in systemic lupus erythematosus

1 reference

12 December 2020

Chloroquine inhibits processing of tumor necrosis factor in lipopolysaccharide-stimulated RAW 264.7 macrophages

1 reference

12 December 2020

Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity

1 reference

12 December 2020

Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells.

1 reference

12 December 2020

The influence of antimalarial treatment on IL-1beta, IL-6 and TNF-alpha mRNA expression on UVB-irradiated skin in systemic lupus erythematosus

1 reference

12 December 2020

Chloroquine inhibits proinflammatory cytokine release into human whole blood.

1 reference

12 December 2020

Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy

1 reference

12 December 2020

Hydroxychloroquine in pregnant patients with systemic lupus erythematosus

1 reference

12 December 2020

Ocular side effects of chloroquine in patients with rheumatoid arthritis, systemic lupus erythematosus and scleroderma.

1 reference

12 December 2020

Effects of antimalarial drugs on phospholipase A and lysophospholipase activities in plasma membrane, mitochondrial, microsomal and cytosolic subcellular fractions of rat liver

1 reference

12 December 2020

Mechanisms of action of antimalarials in inflammation: induction of apoptosis in human endothelial cells

1 reference

12 December 2020

Ophthalmologic considerations in using antimalarials in the United States

1 reference

12 December 2020

The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus.

1 reference

12 December 2020

Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus.

1 reference

12 December 2020

Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis.

1 reference

12 December 2020

The efficacy of antimalarials in systemic lupus erythematosus

1 reference

12 December 2020

Retinopathy and antimalarial drugs--the British experience.

1 reference

12 December 2020

Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.150

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/NRNEPH.2011.150

1 reference

25 August 2017

1 reference